How to Ease Tensions With ICE Agents in Minneapolis

Watch on YouTube ↗  |  January 15, 2026 at 20:43  |  7:50  |  Bloomberg Markets
Speakers
Nicole Malliotakis — Republican Congresswoman, New York

Summary

Rep. Nicole Malliotakis discusses credit-card interest-rate caps, healthcare affordability, PBM reform, drug pricing, immigration enforcement, and DHS funding. She criticizes PBM vertical integration and lack of transparency, supports reviewing most-favored-nation drug pricing, and sees a possible reconciliation path for healthcare and housing. On immigration, she backs border security and criminal deportations but says ICE raids need more balance and local cooperation. She also warns a DHS funding fight could affect the Coast Guard and other security programs.

  • Rep. Malliotakis opposes broad price controls but calls 29% credit-card rates excessive and suggests an 18% cap could be considered.
  • She says PBM reform is a major healthcare issue and backs scrutiny of vertically integrated PBMs.
  • She supports reviewing most-favored-nation drug pricing to lower U.S. drug costs.
  • She sees reconciliation as a possible route for healthcare and housing legislation.
  • She supports border security and criminal deportations but wants more balanced ICE enforcement.
  • She warns a DHS funding fight could hurt the Coast Guard, counterterrorism, and cybersecurity.
  • She calls for immigration reform to fix parole, work-authorization, and visa delays.
Ideas
Nicole Malliotakis Republican Congresswoman, New York 0:06
Credit-card rate cap policy risk builds
Rep. Malliotakis says 29% credit-card rates are excessive and suggests a credit-union-style 18% cap could be considered, even as she voices Republican concerns about price controls. The debate creates a policy overhang for credit-card companies and lenders, with Capitol Hill likely to remain focused on affordability and rate caps.
Credit card companies LOW
Nicole Malliotakis Republican Congresswoman, New York 1:50
Drug-pricing reform pressures pharmaceuticals
She supports the president's most-favored-nation drug pricing proposal, arguing Americans should pay the same prices as other countries and questioning why the U.S. subsidizes research while paying the highest prices. That stance points to continued drug-pricing policy pressure on the pharmaceutical sector.
XLV LOW
Nicole Malliotakis Republican Congresswoman, New York 2:07
PBMs face rising U.S. regulatory scrutiny
She says PBM reform is a bigger healthcare issue than headline drug pricing. PBMs are vertically integrated middlemen between insurers and pharmacies that put small pharmacies out of business, dictate competitor pricing, lack transparency, and have increased profits 230% while premiums rise despite taxpayer subsidies. Ways and Means will question health insurance executives who also own PBMs, creating regulatory and reputational risk for the PBM sector.
PBMs HIGH
Up Next
35:36
Will software survive in the AI-coding era?
CNBC · Jan 15
4:19
Goldman Stock Traders Smash Records as BlackRock Assets Hit $14 Trillion
Bloomberg Markets · Jan 15
10:21
A França vai acabar? Imigração, fertilidade e o futuro da Europa
Fernando Ulrich · Jan 15
4:21
Good time for Fed to wait and see as economy is running hot: Former Fed president Dennis Lockhart
CNBC · Jan 15
16:03
Watch CNBC's full interview with U.S. Secretary of Commerce Howard Lutnick
CNBC · Jan 15

This Bloomberg Markets video, published January 15, 2026, features Nicole Malliotakis discussing Credit card companies, XLV, PBMs. 3 trade ideas extracted by AI with direction and confidence scoring.

Speakers: Nicole Malliotakis  · Tickers: Credit card companies, XLV, PBMs